On this page

Nystatin

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Nystatin
Generic name
Nystatin
Dosage form
Ointment
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
15
Packages
25
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 100000 1/g 261178 View
Nystatin 100000 U/g 261178 View
Nystatin 100000 [USP'U]/g 261178 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Ointment
Route of administration
Topical
Presentations
40

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
207767
Application type
ANDA · Abbreviated New Drug Application
Approval date
May 25, 2018
Sponsor
ZYDUS LIFESCIENCES
Products on application
1
Submissions recorded
1
Products approved under application 207767.
Product Trade name Form Strength Ingredient Status TE Flags
207767-001 NYSTATIN OINTMENT NYSTATIN Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 207767.
Type No. Action Status Date Review
Original application 1 Approved May 25, 2018 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260508). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260508 HUMAN PRESCRIPTION DRUG · 20250403 HUMAN PRESCRIPTION DRUG · 20231129 HUMAN PRESCRIPTION DRUG · 20231030

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin Ointment, USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candidaspecies. Nystatin Ointment, USP is not indicated for systemic, oral, intravaginal or ophthalmic use.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Nystatin Ointment USP should be applied liberally to affected areas twice a day or as indicated until healing is complete. Nystatin cream is usually preferred to nystatin ointment in candidiasis involving intertriginous areas; very moist lesions, however, are best treated with nystatin topical powder. This preparation does not stain skin or mucous membranes and provides a simple, convenient means of treatment.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Nystatin ointment, USP is contraindicated in patients with a history of hypersensitivity to any of its components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The frequency of adverse events reported in patients using Nystatin Ointment preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General.) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-338 or FDA at 1-800-FDA-1088 ( www.fda.gov/medwatch ).

Description

openFDA Drug Labeling

DESCRIPTION Nystatin Ointment, USP is for dermatologic use. Nystatin Ointment, USP for topical use only, contains 100,000 USP nystatin units per gram, in a white petrolatum base. Nystatin is a polyene antifungal antibiotic drug obtained from Streptomyces nursei . The structural formula is as follows: Molecular Weight 926.13 Molecular Formula C 47 H 75 NO 17 image description

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystatin ointment USP, 100,000 units per gram is a pale yellow to yellow color ointment available as follows: NDC 13668-534-01 15 gram tube NDC 13668-534-02 30 gram tube STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Manufactured by: Torrent Pharmaceuticals LTD., Pithampur-454775, INDIA . Manufactured for: Torrent Pharma INC., Basking Ridge, NJ 07920 8102492 Revised: March 2026 Image

Adverse event reports

Source: openFDA FAERS
27,387
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-5845-0 50090-5845 A-S Medication Solutions 15 g in 1 TUBE (50090-5845-0) November 4, 2021
0472-0166-15 0472-0166 Actavis Pharma, Inc. 1 TUBE in 1 CARTON (0472-0166-15) / 15 g in 1 TUBE September 3, 2002
0472-0166-30 0472-0166 Actavis Pharma, Inc. 1 TUBE in 1 CARTON (0472-0166-30) / 30 g in 1 TUBE September 3, 2002
63629-2515-1 63629-2515 Bryant Ranch Prepack 30 g in 1 TUBE (63629-2515-1) May 18, 2021
63629-2516-1 63629-2516 Bryant Ranch Prepack 15 g in 1 TUBE (63629-2516-1) May 18, 2021
72162-2007-2 72162-2007 Bryant Ranch Prepack 15 g in 1 TUBE (72162-2007-2) February 6, 2024
72162-2007-3 72162-2007 Bryant Ranch Prepack 30 g in 1 TUBE (72162-2007-3) February 6, 2024
72162-2333-2 72162-2333 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2333-2) / 15 g in 1 TUBE June 18, 2024
72162-2333-3 72162-2333 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2333-3) / 30 g in 1 TUBE June 18, 2024
0713-0686-15 0713-0686 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0686-15) / 15 g in 1 TUBE July 30, 2018
0713-0686-31 0713-0686 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0686-31) / 30 g in 1 TUBE July 30, 2018
69315-307-15 69315-307 Leading Pharma, LLC 1 TUBE in 1 CARTON (69315-307-15) / 15 g in 1 TUBE August 19, 2019
69315-307-30 69315-307 Leading Pharma, LLC 1 TUBE in 1 CARTON (69315-307-30) / 30 g in 1 TUBE August 19, 2019
33342-481-15 33342-481 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-481-15) / 15 g in 1 TUBE January 29, 2021
33342-481-30 33342-481 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-481-30) / 30 g in 1 TUBE January 29, 2021
45802-048-11 45802-048 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-048-11) / 30 g in 1 TUBE November 8, 2006
45802-048-35 45802-048 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-048-35) / 15 g in 1 TUBE September 15, 2006
63187-464-15 63187-464 Proficient Rx LP 1 TUBE in 1 CARTON (63187-464-15) / 15 g in 1 TUBE January 1, 2019
71205-437-15 71205-437 Proficient Rx LP 1 TUBE in 1 CARTON (71205-437-15) / 15 g in 1 TUBE March 19, 2020
13668-534-01 13668-534 Torrent Pharmaceuticals Limited 15 g in 1 TUBE (13668-534-01) January 29, 2019
13668-534-02 13668-534 Torrent Pharmaceuticals Limited 30 g in 1 TUBE (13668-534-02) January 29, 2019
72578-089-01 72578-089 Viona Pharmaceuticals Inc 15 g in 1 TUBE (72578-089-01) June 24, 2020
72578-089-04 72578-089 Viona Pharmaceuticals Inc 30 g in 1 TUBE (72578-089-04) June 24, 2020
70771-1357-1 70771-1357 Zydus Lifesciences Limited 15 g in 1 TUBE (70771-1357-1) August 8, 2018
70771-1357-2 70771-1357 Zydus Lifesciences Limited 30 g in 1 TUBE (70771-1357-2) August 8, 2018
50090-5845 50090-5845 A-S Medication Solutions — June 24, 2020
0472-0166 0472-0166 Actavis Pharma, Inc. — September 3, 2002
63629-2515 63629-2515 Bryant Ranch Prepack — June 24, 2020
63629-2516 63629-2516 Bryant Ranch Prepack — June 24, 2020
72162-2007 72162-2007 Bryant Ranch Prepack — June 24, 2020
72162-2333 72162-2333 Bryant Ranch Prepack — September 15, 2006
0713-0686 0713-0686 Cosette Pharmaceuticals, Inc. — October 6, 2017
69315-307 69315-307 Leading Pharma, LLC — August 19, 2019
33342-481 33342-481 Macleods Pharmaceuticals Limited — January 29, 2021
45802-048 45802-048 Padagis Israel Pharmaceuticals Ltd — September 15, 2006
63187-464 63187-464 Proficient Rx LP — September 3, 2002
71205-437 71205-437 Proficient Rx LP — October 6, 2017
13668-534 13668-534 Torrent Pharmaceuticals Limited — January 29, 2019
72578-089 72578-089 Viona Pharmaceuticals Inc — June 24, 2020
70771-1357 70771-1357 Zydus Lifesciences Limited — August 8, 2018

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.